CG
MRSN

Cutler Group’s Mersana Therapeutics MRSN Stock Holding History

Cutler Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,200
Closed -$5K – 4134
2023
Q2 		$5K Buy
+1,200
New +$176K ﹤0.01% 2630
2021
Q1 		– Sell
-828
Closed -$26K – 6052
2020
Q4 		$26K Buy
828
+812
+5,075% +$452K ﹤0.01% 2483
2020
Q3 		$2K Sell
16
-416
-96% -$210K ﹤0.01% 4076
2020
Q2 		$42K Buy
+432
New +$148K ﹤0.01% 1862

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Cutler Group's MRSN Position: Q2 2023 in Review

Cutler Group sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 48 shares — an estimated $7.02K sold.

Cutler Group first reported a position in MRSN in Q1 2020 and held it in 11 quarters. The position peaked at $78K in Q2 2021. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Cutler Group reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cutler Group sold 48 Mersana Therapeutics shares in Q2 2023, an estimated $7.02K.
  • Cutler Group first reported a position in Mersana Therapeutics in Q1 2020 and held it in 11 quarters.
  • Cutler Group's Mersana Therapeutics position peaked at $78K in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.